Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 14/20 | 0.71 |
| ▸ | THRB | P10828 | 14/20 | 0.71 |
| ▸ | AR | P10275 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109789 | 0.94 | THRA (0.68) | THRATHRBARESR1NR3C1 | |
| SCHEMBL5103388 | 0.93 | THRA (0.75) | THRATHRBARESR1NR3C1 | |
| SCHEMBL4360347 | 0.88 | THRA (0.73) | THRATHRBARESR1NR3C1 | |
| SCHEMBL4346625 | 0.85 | THRA (0.69) | THRATHRBARESR1NR3C1 | |
| SCHEMBL4360199 | 0.84 | THRA (0.67) | THRATHRBARESR1NR3C1 | |
| SCHEMBL4353533 | 0.83 | THRA (0.84) | THRATHRBARESR1NR3C1 | |
| SCHEMBL4355776 | 0.83 | THRA (0.79) | THRATHRBARESR1NR3C1 | |
| SCHEMBL4351420 | 0.82 | THRA (0.75) | THRATHRBARESR1NR3C1 | |
| SCHEMBL4541153 | 0.82 | THRA (0.80) | THRATHRBARESR1NR3C1 | |
| SCHEMBL4348412 | 0.81 | THRA (0.77) | THRATHRBARESR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | KARO BIO AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | TSHR, TRHR, THRA | THRA 3/4885THRB 4/4885AR 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.